In OSCC patients, S1P-metabolising enzymes, after measuring the mRNA levels, were found to be significantly altered, correlating with clinicopathological attributes and host metabolism, with the expression of SphK1- and S1P-metabolising enzymes found to be significantly upregulated in OSCC patient tumours [105]. This evidence concerns the gene SPHK1 and neoplasm.